Community-acquired pneumonia primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 20: | Line 20: | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Pneumococcal polysaccharide vaccine | | style="padding: 5px 5px; background: #F5F5F5;" |Pneumococcal polysaccharide vaccine | ||
| style="padding: 5px 5px; background: #F5F5F5;" |All persons > 65 years of age, high-risk persons 2–64 years of age, current smokers | | style="padding: 5px 5px; background: #F5F5F5;" |All persons > 65 years of age, high-risk persons 2–64 years of age, current smokers | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Chronic [[cardiovascular]], [[pulmonary]], [[renal]], or [[liver disease]] | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Chronic [[cardiovascular]], [[pulmonary]], [[renal]], or [[liver disease]] | |||
*[[Diabetes mellitus]], | |||
*Cerebrospinal fluid leaks | |||
*[[Alcoholism]] | |||
*[[Asplenia]] | |||
*Immunocompromising conditions/medications | |||
*Native Americans and Alaska natives | |||
*Long-term care facility residents | |||
| style="padding: 5px 5px; background: #F5F5F5;" | One-time revaccination after 5 years for: | | style="padding: 5px 5px; background: #F5F5F5;" | One-time revaccination after 5 years for: | ||
*Adults > 65 years of age, if the first dose is received before age 65 years | *Adults > 65 years of age, if the first dose is received before age 65 years | ||
| Line 31: | Line 39: | ||
| style="padding: 5px 5px; background: #F5F5F5;" |All persons > 50 years of age, High-risk persons 6 months–49 years of age, household contacts of high-risk | | style="padding: 5px 5px; background: #F5F5F5;" |All persons > 50 years of age, High-risk persons 6 months–49 years of age, household contacts of high-risk | ||
persons, health care providers, children 6–23 months of age | persons, health care providers, children 6–23 months of age | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Chronic cardiovascular or pulmonary disease (including [[asthma]]) | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Chronic cardiovascular or pulmonary disease (including [[asthma]]) | |||
*Chronic metabolic disease (including [[diabetes mellitus]]) | |||
*Renal dysfunction | |||
*[[Hemoglobinopathies]] | |||
*Immunocompromising conditions/medications | |||
*Compromised respiratory function or increased aspiration risk | |||
*[[Pregnancy]] | |||
*[[Aspirin]] therapy in persons < 18 years of age | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Annualy | | style="padding: 5px 5px; background: #F5F5F5;" |Annualy | ||
|- | |- | ||
Revision as of 15:45, 10 December 2014
|
Community-Acquired Pneumonia Microchapters |
|
Differentiating Community-acquired pneumonia from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Community-acquired pneumonia primary prevention On the Web |
|
American Roentgen Ray Society Images of Community-acquired pneumonia primary prevention |
|
Directions to Hospitals Treating Community-acquired pneumonia |
|
Risk calculators and risk factors for Community-acquired pneumonia primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Overview
There are several ways to prevent infectious pneumonia. Appropriately treating underlying illnesses (such as AIDS), smoking cessation, vaccination against pneumococcal and influenza are the commonly used methods.
Vaccination
| Vaccine | Route of Administration | Type of Vaccine | Recommended Groups | Specific high-risk indications for vaccination | Re-vaccination schedule |
|---|---|---|---|---|---|
| Pneumococcal Vaccine | Intramuscular injection | Pneumococcal polysaccharide vaccine | All persons > 65 years of age, high-risk persons 2–64 years of age, current smokers |
|
One-time revaccination after 5 years for:
|
| Inactivated Influenza Vaccine | Intramuscular injection | Killed virus | All persons > 50 years of age, High-risk persons 6 months–49 years of age, household contacts of high-risk
persons, health care providers, children 6–23 months of age |
|
Annualy |
| Live Attenuated Influenza Vaccine | Intranasal spray | Live virus | Healthy persons 5–49 years of age,a including health care providers and household contacts of high-risk persons | Avoid in high-risk persons | Annualy |
| Adapted from IDSA/ATS Consensus Guidelines on the Vaccine Prevention for Community-Acquired Pneumonia in Adults. [1] | |||||
References
- ↑ Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG (2007). "Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults". Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 44 Suppl 2: S27–72. doi:10.1086/511159. PMID 17278083. Retrieved 2012-09-06. Unknown parameter
|month=ignored (help)